


Fonatsch, C., Gutat, H., Lengfelder, E. et al. (1994) Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia, 8, 1318-1326.


Greinix, H.T., Reiter, E., Kel, F. et al. (1998) Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. Bone Marrow Transplant, 21, 673-678.


Lee, E.J., George, S.L., Amrein, P.C. et al. (1998) An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. Leukemia, 12, 139-143.


Mrozek, K., Heineon, K., Lawrence, D. et al. (1997) Adult patients with de novo acute myeloid leukemia and t(9;11)(p22; q23) have a superior outcome to other translocations involving band 11q23: a cancer and leukemia group B study. Blood, 90, 4532-4538.


Ruutu, T., Almqvist, A., Hallman, H. et al. (1994) Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia, 8, 11-15.


Schloch, C., Haase, D., Haferlach, T. et al. (1996) Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia, 10, 1288-1295.


Visani, G., Lemoli, R., Tosi, P. et al. (1999) Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant, 24, 467-472.


Weissman, M., Haferlach, C., Haferlach, T., Schnittger, S. (2007) Advanced age and high initial WBC influence the outcome of inv(3)(q21q26) and t(3;3)(q21;q26) positive AML. Leuk Lymphoma, 48, 2145-51.


